Development of a microsimulation model to project the future prevalence of childhood cancer in Ontario, Canada
Moskalewicz A, Gupta S, Nathan PC, Pechlivanoglou P. Med Decis Making. 2025; 272989X251314031. Epub 2025 Feb 4.
Recently, the evidence-based drug funding process in Ontario, Canada, was challenged by a young mother with a breast tumor too small, based on the evidence that existed at the time, to qualify for an expensive drug. In reality, this is only the latest in a number of challenges the publicly funded healthcare system has had to deal with in the face of an evolving drug policy landscape. This article defines comparative effectiveness research (CER), considering how it is viewed differently in the United States and Canada. It also reviews the role CER now plays in the Ontario drug funding process and concludes with a review of the challenges and opportunities of using observational data to conduct CER and incorporate it into policy making within a universal healthcare system. Many of the issues faced by Ontario are relevant beyond Canada, including in the United States during this period of healthcare reform.
Hoch JS, Hodgson DC, Earle CC. J Clin Oncol. 2012; 30(34):4262-6. Epub 2012 Oct 15.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.